Compare · DFTX vs SMFL
DFTX vs SMFL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Smart for Life Inc. (SMFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SMFL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $5.10B.
- Over the past year, DFTX is up 305.5% and SMFL is up 0.0% - DFTX leads by 305.5 points.
- DFTX has hit the wire 7 times in the past 4 weeks while SMFL has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 0 for SMFL).
- Company
- Definium Therapeutics Inc.
- Smart for Life Inc.
- Price
- $37.83-0.58%
- $0.83-17.00%
- Market cap
- $5.10B
- -
- 1M return
- -7.52%
- +0.00%
- 1Y return
- +305.47%
- +0.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 7
- 0
- Recent ratings
- 7
- 0
Smart for Life Inc.
Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements; dietary supplements; nutritional supplements for athletes and active lifestyle consumers comprising powders, tablets, and soft gels; and various nutritional supplements. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Miami, Florida.
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
Latest SMFL
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 25-NSE filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SEC Form SC 13G/A filed by Smart for Life Inc.
- SEC Form NT 10-Q filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Smart for Life Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Smart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring Efforts
- Smart for Life Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing